HK1206771A1 - 作為脂肪酸結合蛋白 和/ 的抑制劑的非成環噻吩基酰胺 - Google Patents
作為脂肪酸結合蛋白 和/ 的抑制劑的非成環噻吩基酰胺Info
- Publication number
- HK1206771A1 HK1206771A1 HK15107161.1A HK15107161A HK1206771A1 HK 1206771 A1 HK1206771 A1 HK 1206771A1 HK 15107161 A HK15107161 A HK 15107161A HK 1206771 A1 HK1206771 A1 HK 1206771A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- fabp
- thiophenylamides
- proteini
- annulated
- inhibitors
- Prior art date
Links
- 235000014113 dietary fatty acids Nutrition 0.000 title 1
- 229930195729 fatty acid Natural products 0.000 title 1
- 239000000194 fatty acid Substances 0.000 title 1
- 150000004665 fatty acids Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12184125 | 2012-09-12 | ||
PCT/EP2013/068565 WO2014040938A1 (en) | 2012-09-12 | 2013-09-09 | Non-annulated thiophenylamides as inhibitors of fatty acid binding proteini(fabp) 4 and/or 5 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1206771A1 true HK1206771A1 (zh) | 2016-01-15 |
Family
ID=46967985
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15107161.1A HK1206771A1 (zh) | 2012-09-12 | 2015-07-27 | 作為脂肪酸結合蛋白 和/ 的抑制劑的非成環噻吩基酰胺 |
Country Status (13)
Country | Link |
---|---|
US (1) | US9353102B2 (zh) |
EP (1) | EP2895481B1 (zh) |
JP (1) | JP6383357B2 (zh) |
KR (1) | KR20150054821A (zh) |
CN (1) | CN104619705B (zh) |
AR (1) | AR092496A1 (zh) |
BR (1) | BR112015004008A8 (zh) |
CA (1) | CA2878804A1 (zh) |
HK (1) | HK1206771A1 (zh) |
MX (1) | MX2015002624A (zh) |
RU (1) | RU2647587C2 (zh) |
TW (1) | TW201416364A (zh) |
WO (1) | WO2014040938A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101834857B1 (ko) * | 2015-01-05 | 2018-03-07 | 서울대학교산학협력단 | 제2형 당뇨병의 조기 진단을 위한 단백질 바이오 마커 |
EA201892045A1 (ru) * | 2016-03-11 | 2019-04-30 | Те Рисерч Фаундейшн Фор Те Стейт Юниверсити Оф Нью Йорк | ПРОИЗВОДНЫЕ α-ТРУКСИЛЛОВОЙ КИСЛОТЫ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ С НИМИ |
CN111690727A (zh) * | 2019-03-12 | 2020-09-22 | 南方医科大学南方医院 | Fabp5作为新型生物标志物用于诊断动脉粥样硬化 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1676834A1 (en) * | 2004-12-30 | 2006-07-05 | Sanofi-Aventis Deutschland GmbH | Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation |
CA2624183A1 (en) * | 2005-09-29 | 2007-04-05 | Inpharmatica Limited | Thiophene derivatives as ppar agonists i |
WO2008109856A2 (en) * | 2007-03-07 | 2008-09-12 | Xenon Pharmaceuticals Inc. | Methods of using diazepinone compounds in treating sodium channel-mediated diseases or conditions |
US20100168084A1 (en) * | 2008-05-08 | 2010-07-01 | Huber L Julie | Therapeutic compounds and related methods of use |
-
2013
- 2013-09-09 MX MX2015002624A patent/MX2015002624A/es unknown
- 2013-09-09 KR KR1020157006187A patent/KR20150054821A/ko not_active Application Discontinuation
- 2013-09-09 EP EP13762429.2A patent/EP2895481B1/en active Active
- 2013-09-09 CA CA2878804A patent/CA2878804A1/en not_active Abandoned
- 2013-09-09 WO PCT/EP2013/068565 patent/WO2014040938A1/en active Application Filing
- 2013-09-09 JP JP2015530434A patent/JP6383357B2/ja not_active Expired - Fee Related
- 2013-09-09 RU RU2015110644A patent/RU2647587C2/ru not_active IP Right Cessation
- 2013-09-09 BR BR112015004008A patent/BR112015004008A8/pt not_active Application Discontinuation
- 2013-09-09 CN CN201380047051.3A patent/CN104619705B/zh not_active Expired - Fee Related
- 2013-09-10 AR ARP130103210A patent/AR092496A1/es unknown
- 2013-09-11 TW TW102132840A patent/TW201416364A/zh unknown
-
2015
- 2015-03-11 US US14/645,012 patent/US9353102B2/en active Active
- 2015-07-27 HK HK15107161.1A patent/HK1206771A1/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
MX2015002624A (es) | 2015-06-23 |
CA2878804A1 (en) | 2014-03-20 |
EP2895481A1 (en) | 2015-07-22 |
BR112015004008A2 (pt) | 2017-07-04 |
TW201416364A (zh) | 2014-05-01 |
RU2647587C2 (ru) | 2018-03-16 |
US20150183778A1 (en) | 2015-07-02 |
WO2014040938A1 (en) | 2014-03-20 |
CN104619705B (zh) | 2018-01-02 |
JP2015527384A (ja) | 2015-09-17 |
KR20150054821A (ko) | 2015-05-20 |
US9353102B2 (en) | 2016-05-31 |
BR112015004008A8 (pt) | 2018-01-23 |
RU2015110644A (ru) | 2016-11-10 |
CN104619705A (zh) | 2015-05-13 |
AR092496A1 (es) | 2015-04-22 |
EP2895481B1 (en) | 2019-12-11 |
JP6383357B2 (ja) | 2018-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1225390A1 (zh) | 作為精氨酸酶抑制劑的硼酸鹽及其組合物和用途 | |
EP2861227A4 (en) | OMEGA-3 PENTAIC ACID COMPOSITIONS AND METHODS OF USE | |
HK1210957A1 (zh) | 外排抑制劑組合物和使用此組合物治療的方法 | |
RS58892B1 (sr) | Jedinjenja 3-aminocikloalkila kao inhibitori ror-gama-t i njihove upotrebe | |
AP3965A (en) | Anthelminitic compounds and compositions and method of using thereof | |
HK1210470A1 (zh) | 用作脂肪酸合成酶抑制劑的氫吡咯並吡咯衍生物 | |
EP2884981A4 (en) | BENZOIC ACID COMPOUNDS SUBSTITUTED WITH 4-HETEROARYL AS RORGAMMAT INHIBITORS AND USES THEREOF | |
SG11201406512WA (en) | Method for the production of acrylic acid or its derivatives | |
SG11201503646TA (en) | Esterification of 2,5-furan-dicarboxylic acid | |
EP2844257A4 (en) | Fatty Acid Conjugates from Statin and FXR Agonists; COMPOSITIONS AND METHODS OF USE | |
EP2917358A4 (en) | COMPOSITIONS AND METHODS FOR THE BIOLOGICAL PRODUCTION OF FATTY ACID DERIVATIVES | |
HK1203958A1 (zh) | 磺酰胺化合物及作為 抑制劑的用途 | |
EP2637660A4 (en) | GRAS SYNTHASE ACID INHIBITORS | |
EP2844755A4 (en) | METHODS AND COMPOSITIONS FOR THE EXTRACTION AND STORAGE OF NUCLEIC ACIDS | |
PL2828208T3 (pl) | Aktywowanie kwasu organicznego za pomocą nadsiarczanu | |
EP2827868A4 (en) | PHARMACEUTICAL COMPOSITIONS COMPRISING FATTY ACID ESTERS | |
EP2895586A4 (en) | DETERGENT COMPOSITION COMPRISING PHOSPHINOSUCCINIC ACID ADDITION PRODUCTS AND METHODS OF USE | |
IL236965B (en) | Derivatives of 5-aminolevulinic acid and uses thereof | |
EP2897454A4 (en) | METHOD AND COMPOSITIONS FOR EXTENDING THE DURABILITY OF PLANT PRODUCTS | |
EP2906041A4 (en) | COMPOSITIONS AND METHODS OF USING INAPPETENCE COMPOUND | |
IL221281A0 (en) | Fatty acid amide hydrolase inhibitors | |
EP2929041A4 (en) | PENTAENOIC ACID COMPOSITIONS OF OMEGA-3 AND ASSOCIATED METHODS OF USE | |
EP2857010A4 (en) | Dihydroorotic-DEHYDROGENASEHEMMER | |
EP2845585A4 (en) | COMPOSITION OF FATTY ACID ESTERS OF TRHEHALOSIS | |
HK1206771A1 (zh) | 作為脂肪酸結合蛋白 和/ 的抑制劑的非成環噻吩基酰胺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20210904 |